December 29, 2023 7:47am

Before “dark” actions happen while various overbought and sentiment indicators suggest the market rally could be due for a pause or pullback. The Nasdaq is 7.8% above its 50-day moving average

Subscription is coming, it is not conscription but, an offer to join our collective of like-minded investors!  Join me … in the NO spin zone.

If you want facts to interpret share pricing realities to save your portfolio for cautious decisions, bookmark this site!

Never leave an investor uninformed!

Remember that overnight action in a.m. futures and global markets doesn't necessarily translate into actual trading in the today’s market session.

I make a commitment to provide need-to-know “facts in evidence” as an equity’s volatility is one tactical signal for stocks.

 

The pre-open Dow futures are UP +0.04% or (+14 points), the S&P is UP +0.03% or (+1 points) as the Nasdaq is UP +0.05% or (+8 points)

Stock futures struggling higher on Friday, 12/29/23,

European stocks started the final session of 2023 higher,

Asia Pacific markets wrap up last trading day of 2023 with small declines.

 

Henry’omics:

We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies …

Indexes closed mixed as the Dow closed UP +53.58 points or +0.14%, the S&P closed UP +1.77 points or +0.04% while the Nasdaq closed DOWN -4.04 points or +0.03%

 

Thursday, RegMed Investors (RMi) Closing Bell: “The volatility tug-of-war as volume fell on the Nasdaq while an absence of news has not stopped investors jumping into upside “bets” … https://www.regmedinvestors.com/articles/13262   

 

Q4:  December – 1 holiday, 10 positive and 9 negative closes

  • November – 11 positives, 1 holiday and 10 negative closes
  • October – 1 sick day, 9 positive and 12 negative closes

 

Companies in my headlights – It’s your decision; I provide ideas and context:

I post about “indication intelligence” devoting my time to collection and analysis of information to assist investors with insight into sector vulnerabilities and strengths. A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

I am passing on forecasting the daily indications; it’s just mixed signals, followed by a weak aftermarket as markets end for today’s 2023 final trading session …

If I was to make a “bet”:

Verve Therapeutics (VERV) closed up +$0.28 to $14.95 after Wednesday’s $14.67, Tuesday’s $14.81 and last Friday’s $14.29 with a negative -$0.20 or -1.34% aftermarket indication

Solid Bioscience (SLDB) closed up +$0.21 after Wednesday’s +$0.34 and Tuesday’s +$0.80 and last Friday’s +$0.43 with a negative -$0.23 or -3.42% aftermarket indication

Vericel (VCEL) closed up +$0.64 after Wednesday’s -$0.93 and Tuesday’s +$1.56, Friday’s -$0.75 and the previous Thursday’s +$1.46 with a positive +$0.22 or +0.61% aftermarket/sell into strength indication

 

The BOTTOM LINE: I got the “vid” – covid – didn’t make for a happy, happy holiday week pre–New Year but I make the most of is as I was cook, cleaner, bottle washer (plus drinker) and playing doctor for the “babe” wasn’t fun as

  • Again, and again – I say what changes … as I reiterate … “I remain a skeptic, as electronic trading remains the impetus to, I believe a cell and gene therapy sector’s artificial high” … as proven today yet again!
  • Thin liquidity conditions exacerbate the so-called 'Santa Claus rally' in equities ahead of the turn of the year. 

 

“The market looks increasingly overbought; the Nasdaq is 7.8% above its 50-day moving average even as sentiment indicators point to elevated bullishness. All of that continues to suggest another market pause or pullback is likely.

it's not a time to be aggressive … Investors waiting to sell stocks until January for tax reasons may be delaying that potential pullback, but ultimately that could make the eventual pullback more significant.”

 

Welcome to my world of defining the “grey’ in our universe!

  • Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and facts are its product; I can always be WRONG but … I am mostly EARLY!”

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors could hold or have positions securities referred to in this publication and he will NOTIFY investors of holdings.